Nothing said here yet.
to join the conversation.
| Crystal AdamPresident, R&D | Sell | 26,400 | $645.6K | Thu, Oct 1 |
| Crystal AdamPresident, R&D | Sell | 600 | $15.2K | Thu, Oct 1 |
| Newcomb JessicaPrincipal Accounting Officer | Sell | 5,100 | $122.2K | Tue, Sep 22 |
| Newcomb JessicaPrincipal Accounting Officer | Sell | 2,400 | $60.4K | Tue, Sep 22 |
| Newcomb JessicaPrincipal Accounting Officer | Sell | 700 | $16.0K | Tue, Sep 22 |
| Crystal AdamPresident, R&D | Sell | 27,000 | $603.9K | Tue, Sep 1 |
Tango Therapeutics (TNGX) has drawn fresh attention after reporting updated Phase 1/2 data for vopimetostat combined with RAS(ON) inhibitors in MTAP-deleted, RAS-mutant pancreatic and lung cancers, alongside plans for a global registrational trial.
Is TNGX a good stock to buy? We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch’s Substack.
Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.
Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.
Tango Therapeutics (NASDAQ:TNGX) said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal…
Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.
Key TakeawaysTango Therapeutics shares fell 13% today after new data showed an 82% response rate for its drug vopimetostat combined with Revolution Medicines’ daraxonrasib in 22 pancreatic cancer patients.
Investing.com -- Tango Therapeutics (NASDAQ:TNGX) shares fell 6% Friday following the company’s presentation of Phase 1/2 study results for vopimetostat and daraxonrasib in pancreatic cancer, despite what the company characterized as promising data.
Tango Therapeutics has delivered very strong gains in recent years, and that kind of run naturally raises a simple question for you as a shareholder or potential buyer.